Cannabis and Cannabinoid Research, Год журнала: 2024, Номер unknown
Опубликована: Авг. 26, 2024
The chronic effects of cannabidiol (CBD) supplementation on factors that could impact the quality life (anxiety, sleeping quality, memory, etc.) are poorly explored. Hence, aim this study was to establish whether CBD will improve self-reported outcomes related life.
Язык: Английский
Neuroscience & Biobehavioral Reviews, Год журнала: 2024, Номер 162, С. 105699 - 105699
Опубликована: Май 6, 2024
Robust epidemiological evidence of risk and protective factors for psychosis is essential to inform preventive interventions. Previous syntheses have classified these according their strength association with psychosis. In this critical review we appraise the distinct overlapping mechanisms 25 key environmental psychosis, link mechanistic pathways that may contribute neurochemical alterations hypothesised underlie psychotic symptoms. We then discuss implications our findings future research, specifically considering interactions between factors, exploring universal subgroup-specific improving understanding temporality dynamics, standardising operationalisation measurement developing interventions targeting factors.
Язык: Английский
Процитировано
11
Addiction, Год журнала: 2025, Номер unknown
Опубликована: Фев. 13, 2025
Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as potential therapeutic target due its pharmacological properties mode action in the endocannabinoid system. Recent systematic reviews (SR) on CBD SUDs have shown inconsistent results. The objective this umbrella review was determine whether alone or combination with Δ‐9‐tetrahydrocannabinol (THC) effective for managing treating SUDs. Methods Following registered protocol, we searched PubMed, Web Science Epistemonikos databases SRs, without meta‐analysis, randomized controlled trials focusing interventions dispensing CBD, THC, treat SUDs, published from 1 January 2000 15 October 2024. Screening, data extraction quality assessment AMSTAR 2 tool were performed by two researchers parallel duplicated. Results 22 SRs included, 5 which meta‐analysis. We found mixed evidence regarding efficacy manage Findings interpreted light SRs. Nabiximols, contains demonstrated positive effects cannabis withdrawal craving symptoms. Evidence supporting limited inconclusive abstinence, reduction cessation cannabis, tobacco, alcohol, opiates other psychoactive substances. Conclusion monotherapy does not appear be efficacious substance disorders. primarily exhibits when combined (THC). Existing regard outcomes related
Язык: Английский
Процитировано
2
Addiction, Год журнала: 2023, Номер 118(7), С. 1282 - 1294
Опубликована: Фев. 8, 2023
Long-term harms of cannabis may be exacerbated in adolescence, but little is known about the acute effects adolescents. We aimed to (i) compare adolescent and adult users (ii) determine if cannabidiol (CBD) acutely modulates delta-9-tetrahydocannabinol (THC).Randomised, double-blind, placebo-controlled, crossover experiment. The experiment was registered on ClinicalTrials.gov (NCT04851392).Laboratory London, United Kingdom.Twenty-four adolescents (12 women, 16- 17-year-olds) 24 adults 26- 29-year-olds) who used 0.5-3 days/week were matched use frequency (mean = 1.5 days/week).We administered three weight-adjusted vaporised flower preparations: 'THC' (8 mg THC for 75 kg person); 'THC + CBD' CBD 'PLA' (matched placebo).Primary outcomes subjective 'feel drug effect'; verbal episodic memory (delayed prose recall); (iii) psychotomimetic effect (Psychotomimetic States Inventory).Compared with 'PLA', significantly (P < 0.001) increased effect' difference [MD] 6.3, 95% CI 5.3-7.2; MD 6.8, 6.0-7.7), impaired (MD -2.7, -4.1 -1.4; -2.9, -1.7) 7.8, 2.8-12.7; 10.8, 6.2-15.4). There no evidence that differed from their responses (interaction P ≥ 0.4). Bayesian analyses supported equivalent (Bayes factor [BF01 ] >3). modulated THC.Adolescent are neither more resilient nor vulnerable than psychotomimetic, memory-impairing or cannabis. Furthermore, adults, does not mitigate caused by delta-9-tetrahydocannabinol.
Язык: Английский
Процитировано
21
Neuropsychopharmacology, Год журнала: 2024, Номер 49(10), С. 1640 - 1651
Опубликована: Май 28, 2024
Abstract Adolescence is a time of rapid neurodevelopment and the endocannabinoid system particularly prone to change during this time. Cannabis commonly used drug with high prevalence use among adolescents. The two predominant phytocannabinoids are Delta-9-tetrahydrocannabinol (THC) cannabidiol (CBD), which affect system. It unknown whether period development makes adolescents more or less vulnerable effects cannabis on brain-network connectivity, CBD may attenuate THC. Using fMRI, we explored impact vaporized (placebo, THC: 8 mg/75 kg, THC + CBD: kg & 24 CBD) resting-state networks in groups semi-regular users (usage frequency between 0.5 3 days/week), consisting 22 (16–17 years) young adults (26–29 matched for frequency. caused reductions within-network connectivity default mode (F[2,88] = 3.97, P 0.022, η² 0.018), executive control 18.62, < 0.001, 0.123), salience 12.12, 0.076), hippocampal 14.65, 0.087), limbic striatal 16.19, 0.102) compared placebo. Whole-brain analysis showed significantly disrupted functional cortical regions control, salience, hippocampal, did not counteract THC’s further reduced both within whole brain. While age-related differences were observed, there no interactions age group treatment any brain network. Overall, these results challenge assumption that can make safer, as (and some cases potentiated them); furthermore, they show causes similar disruption adolescent adult
Язык: Английский
Процитировано
9
Pharmaceutics, Год журнала: 2025, Номер 17(3), С. 319 - 319
Опубликована: Март 1, 2025
Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals therapeutic indications, there are challenges minimizing risks interactions between cannabis-based products, prescription drugs, other approved substances of abuse. Thus, identifying enzymes metabolizing cannabinoid drugs their relationship crucial for understanding potential effects simultaneous use. This article offers a comprehensive review pharmacokinetic as well It also compiles existing evidence these describes clinical outcomes associated inhibition or induction various enzymes.
Язык: Английский
Процитировано
1
Cancers, Год журнала: 2023, Номер 15(7), С. 2119 - 2119
Опубликована: Апрель 1, 2023
The application of cannabis products in oncology receives interest, especially from patients. Despite the plethora research data available, added value curative or palliative cancer care and possible risks involved are insufficiently proven therefore a matter debate. We aim to give recommendation on position clinical by assessing recent literature. Various types products, characteristics, quality pharmacology discussed. Standardisation is essential for reliable reproducible quality. oromucosal/sublingual route administration preferred over inhalation drinking tea. Cannabinoids may inhibit efflux transporters drug-metabolising enzymes, possibly inducing pharmacokinetic interactions with anticancer drugs being substrates these proteins. This enhance cytostatic effect and/or drug-related adverse effects. Reversely, it enable dose reduction. Similar likely used symptom management treating pain, nausea, vomiting anorexia. Cannabis usually well tolerated improve life patients (although not unambiguously proven). combination immunotherapy seems undesirable because immunosuppressive action cannabinoids. Further warranted scientifically support (refraining from) using cancer.
Язык: Английский
Процитировано
17
Frontiers in Psychiatry, Год журнала: 2024, Номер 15
Опубликована: Июнь 10, 2024
Various countries and US States have legalized cannabis, the use of psychoactive
Язык: Английский
Процитировано
6
Pain and Therapy, Год журнала: 2024, Номер 13(5), С. 1063 - 1094
Опубликована: Авг. 3, 2024
Interest in medical cannabis and cannabis-based medicinal products (CBMPs) has increased greatly recent years. Two cannabinoids are of principal importance; delta-9-tetrahydrocannabinol (∆9-THC), the primary psychoactive component, also cannabidiol (CBD), considered non-intoxicating. Each distinct mechanisms action different therapeutic potentials. CBMPs differ their ∆9-THC CBD components; predominantly ∆9-THC, balanced formulations with equivalent elements, CBD-predominant products. In this narrative review, we evaluate published evidence for clinical benefits overall well-being. We review safety profile discuss potential dependence CBMPs. Evidence can be drawn from a wide range randomized other controlled studies observational real-world studies. Most data registry supportive ∆9-THC-based (∆9-THC-predominant or CBMPs) management chronic neuropathic pain. Balanced effective reducing spasticity multiple sclerosis. show benefit providing symptomatic anxiety, nausea, improving sleep, but place specific is more subtle, choice guided by circumstances. Symptomatic improvements accompanied improved quality life Safety indicate that generally well tolerated most patients without contraindications. The majority adverse effects non-serious, transient; principally associated dose-dependent. contrast to recreational use, there little have any dependence.
Язык: Английский
Процитировано
5
Frontiers in Psychiatry, Год журнала: 2024, Номер 15
Опубликована: Апрель 23, 2024
Schizophrenia is a serious mental health disorder that confers one of the highest mortality rates all psychiatric illnesses. Although disorder’s psychotic symptoms are treatable with conventional antipsychotics, they remain incurable. Moreover, medication adherence poor, and individuals schizophrenia choose to self-medicate illicit substances, including cannabis. It well-established delta-9-tetrahydrocannabinol (delta-9-THC) component cannabis elicits psychotomimetic effects at high doses; worsens schizophrenia-related psychosis; commonly develops into use in schizophrenia; increases risk earlier-onset those harboring genetic susceptibility. However, derivatives such as cannabidiol (CBD). These products seem alleviate relieve adverse side antipsychotic medications. Therefore, notion has gained traction potential utility cannabis-derived (CBD) adjunct treatment reduce schizophrenia-associated psychosis other symptoms. Currently, preclinical clinical data inconclusive. The present review distinguishes mechanisms underlying vs. cannabis-induced reviews evidence for delta-9-THC-mediated exacerbation CBD-mediated amelioration describes approaches incorporating CBD therapeutic regimen safe efficacious manner.
Язык: Английский
Процитировано
4
Current Addiction Reports, Год журнала: 2024, Номер 11(3), С. 384 - 395
Опубликована: Апрель 15, 2024
Язык: Английский
Процитировано
3